Pinski J - Search Results

1

LHRH and LHR genotypes and prostate cancer incidence and survival.

Ingles SA, Liu SV, Pinski J. Ingles SA, et al. Among authors: pinski j. Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):228-34. eCollection 2013. Int J Mol Epidemiol Genet. 2013. PMID: 24319538 Free PMC article.

2

Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.

Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. Liu SV, et al. Among authors: pinski j. Clin Cancer Res. 2010 Sep 15;16(18):4675-80. doi: 10.1158/1078-0432.CCR-10-1113. Epub 2010 Jul 29. Clin Cancer Res. 2010. PMID: 20670943

3

Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.

Liu SV, Liu S, Pinski J. Liu SV, et al. Among authors: pinski j. Expert Opin Investig Drugs. 2011 Jun;20(6):769-78. doi: 10.1517/13543784.2011.574611. Epub 2011 Mar 31. Expert Opin Investig Drugs. 2011. PMID: 21449823 Review.

4

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.

Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. Pinski J, et al. Prostate. 2011 Jun 1;71(8):892-8. doi: 10.1002/pros.21305. Epub 2010 Nov 17. Prostate. 2011. PMID: 21456071

5

Effects of luteinizing hormone receptor signaling in prostate cancer cells.

Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski J. Xiong S, et al. Among authors: pinski j. Prostate. 2015 Feb;75(2):141-50. doi: 10.1002/pros.22899. Epub 2014 Nov 12. Prostate. 2015. PMID: 25393079

6

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer.

Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. Yu SS, et al. Among authors: pinski j. Clin Genitourin Cancer. 2017 Dec;15(6):742-749. doi: 10.1016/j.clgc.2017.06.002. Epub 2017 Jun 8. Clin Genitourin Cancer. 2017. PMID: 28668277 Clinical Trial.

7

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Liu SV, et al. Among authors: pinski jk. Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2. Clin Cancer Res. 2014. PMID: 25278449 Clinical Trial.

8

Ethnic differences in neuroendocrine expression in prostate cancer tissue.

Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J. Dorff TB, et al. Among authors: pinski j. Anticancer Res. 2011 Nov;31(11):3897-901. Anticancer Res. 2011. PMID: 22110216

9

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).

Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N. Goldkorn A, et al. Among authors: pinski jk. Clin Cancer Res. 2021 Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26. Clin Cancer Res. 2021. PMID: 33500355 Free PMC article. Clinical Trial.

10

Expression of the luteinizing hormone receptor (LHR) in ovarian cancer.

Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, Gaur RK, Epstein AL, Pinski J. Xiong S, et al. Among authors: pinski j. BMC Cancer. 2019 Nov 15;19(1):1114. doi: 10.1186/s12885-019-6153-8. BMC Cancer. 2019. PMID: 31729966 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page